A new SEC filing for Medtronic plc (MDT) triggered this report, reflecting updated disclosures as of mid-June 2026. No additional briefing-level news items were provided in the current context window for the period ending 2026-06-19.
Medtronic's trailing twelve-month revenue stood at $36.36 billion, representing year-over-year growth of 8.74% [SEC 10-Q - MDT - 2026-01-23]. Gross margin was recorded at 53.63%, with an operating margin of 17.78% and a net margin of 13.20%. Net income for the TTM period reached $4.80 billion, while earnings per share declined 11.88% year-over-year. The company carried $1.95 billion in cash against total debt of $23.93 billion. Market capitalisation at the reporting date was approximately $101.57 billion, with a price-to-earnings ratio of 21.27 [SEC 10-Q - MDT - 2026-01-23].
Insider activity over the past 30 days recorded 13 transactions with a net direction of selling, representing a combined net disposal value of approximately $336,965 [SEC Form 4 - MDT - 2026-06]. No institutional 13F filing data was included in the current context, so holdings changes from named filers are not reported here.
The broader fixed-income environment shows the 10-year US Treasury yield at 4.49% and the 2-year yield at 4.20%, producing a normal yield curve spread of 29 basis points [FRED DGS10; FRED DGS2]. Medtronic carries a substantial long-term debt load of $23.93 billion, making prevailing interest rate levels a relevant feature of its financial structure as reported in current filings [SEC 10-Q - MDT - 2026-01-23].